Peptide ELISA: 1/16000. Western Blot: 2 - 3 μg/mL. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions
For Research Use only
Concentration
0,5 mg/mL
Buffer
Tris saline, 0.02 % sodium azide, pH 7.3 with 0.5 % bovine serum albumin
Preservative
Sodium azide
Precaution of Use
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handling Advice
Avoid repeated freezing and thawing.
Storage
4 °C/-20 °C
Storage Comment
Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.
The cannabinoid delta-9-tetrahydrocannabinol is the principal psychoactive ingredient of marijuana. The proteins encoded by this gene and the cannabinoid receptor 1 (brain) (CNR1) gene have the characteristics of a guanine nucleotide-binding protein (G-protein)-coupled receptor for cannabinoids. They inhibit adenylate cyclase activity in a dose-dependent, stereoselective, and pertussis toxin-sensitive manner. These proteins have been found to be involved in the cannabinoid-induced CNS effects (including alterations in mood and cognition) experienced by users of marijuana. The cannabinoid receptors are members of family 1 of the G-protein-coupled receptors. Cannabinoids exert their well known physiological effects through two G protein coupled receptors, cannabinoid receptor 1 (CB1) and CB2. Both cannabinoid receptors have been shown to inhibit adenylyl cyclase as well as stimulate the mitogen-activated protein kinase, MAPK. CB1 receptors also modulate ion channels through direct G-protein interactions. Delta 9-tetrahydrocannibinol and related ligands likely exert their psychoactive effects by inhibiting presynaptic N- and P / Q type calcium channels. CB2 is thought to function primarily in the immune system although it has been suggested to be present in the central nervous system, including the retina.Synonyms: CB-2, CB2, CNR2, CX5, hCB2